Fundz Deep Dive
Everything you need to win Arrowhead — in one platform.
Who to reach, what to say, and why now on Arrowhead — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Arrowhead — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Arrowhead Pharmaceuticals and Sarepta Therapeutics Sign Global License and Collaboration Agreement for Multiple Clinical and Preclinical Programs
Contract Type
agreement
PasadenaManufacturingDescription
Arrowhead Pharmaceuticals, Inc. has announced a global licensing and collaboration agreement with Sarepta Therapeutics, involving an upfront payment of $825 million, cash and equity investments, along with potential future milestone payments and royalties on commercial sales. The agreement encompasses multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs, extending Arrowhead's cash runway and potentially leading to new drug launches.